普門科技(688389.SH):智信生物的系列內窺鏡產品大部分仍在研發、註冊和獲證階段
格隆匯6月6日丨有投資者向普門科技(688389.SH)提問:目前智信生物一次性內窺鏡已取得以及進行中的產品證有哪些?
普門科技回覆:公司在內窺鏡領域的佈局,旨在與臨牀醫療(“呼麻重症”)形成整體的解決方案。智信生物的系列內窺鏡產品大部分仍在研發、註冊和獲證階段。目前已獲證的為可視喉鏡和一次性電子腎盂鏡兩個產品,已獲證產品在國內外進行市場推廣中,可視喉鏡與公司治療康復產品線的“呼麻重症”相關產品客户協同性較強,已結合這些渠道和終端客户基礎進行市場推廣和銷售。未來公司會加大在這一領域的持續投入,陸續完善和上市相關產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.